We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein (HSIC) Tops Q2 Earnings, Revenue Estimates
Read MoreHide Full Article
Headquartered in Melville, NY, Henry Schein Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #3 (Hold) but that could change following its impressive second quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at $1.62 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.64 beat this estimate by 1.2%.
Revenues: Henry Schein posted revenues of $2.87 billion, beating the Zacks Consensus Estimate for revenues of $2.84 billion.
Key Stats: Revenues derived from Henry Schein’s Dental segment grew 4% year over year to $1.4 billion, while Animal Health segment recorded sales of $853.6 million, up 14% compared with the prior-year quarter. Revenues from Medical segment increased 14.5% year over year to $538.8 million, while sales from Technology and Value-added services segment grew 19.6% to $107 million.
Major Factors: Henry Schein ended second quarter of 2016 on an impressive note, with all four of its operating segments delivering strong year over year growth. Management was particularly upbeat with strategic acquisitions that the company made in its technology and Value–Added Services segment. However, we are disappointed to note that Henry Schein reduced the upper end of its adjusted EPS guidance for 2016, by 5 cents.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Henry Schein (HSIC) Tops Q2 Earnings, Revenue Estimates
Headquartered in Melville, NY, Henry Schein Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 28 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #3 (Hold) but that could change following its impressive second quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at $1.62 per share over the last 60 days. Henry Schein’s adjusted earnings per share of $1.64 beat this estimate by 1.2%.
HENRY SCHEIN IN Price and EPS Surprise
HENRY SCHEIN IN Price and EPS Surprise | HENRY SCHEIN IN Quote
Revenues: Henry Schein posted revenues of $2.87 billion, beating the Zacks Consensus Estimate for revenues of $2.84 billion.
Key Stats: Revenues derived from Henry Schein’s Dental segment grew 4% year over year to $1.4 billion, while Animal Health segment recorded sales of $853.6 million, up 14% compared with the prior-year quarter. Revenues from Medical segment increased 14.5% year over year to $538.8 million, while sales from Technology and Value-added services segment grew 19.6% to $107 million.
Major Factors: Henry Schein ended second quarter of 2016 on an impressive note, with all four of its operating segments delivering strong year over year growth. Management was particularly upbeat with strategic acquisitions that the company made in its technology and Value–Added Services segment. However, we are disappointed to note that Henry Schein reduced the upper end of its adjusted EPS guidance for 2016, by 5 cents.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>